Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin and Sorafenib in Advanced Hepatocellular Carcinoma
NCT02358395Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Feb 2015
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of napabucasin in hepatocellular carcinoma (HCC), sponsored by Sumitomo Pharma. Primary endpoints: Assessment of safety and tolerability of BBI608 given in combination with Sorafenib by reporting of adverse events and serious adverse events at 7 months, Assessment of dose-limiting toxicities at 29 days and 1 more. Started Feb 2015; status: completed.
02
Drugs
napabucasin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02358395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358395.